Aldeyra Therapeutics, Inc. (ALDX)
Q1-CY2026Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014Q1-CY2014
Balance Sheet Date2025-Dec-312025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-312023-Sep-302023-Jun-302023-Mar-312022-Dec-312022-Sep-302022-Jun-302022-Mar-312021-Dec-312021-Sep-302021-Jun-302021-Mar-312020-Dec-312020-Sep-302020-Jun-302020-Mar-312019-Dec-312019-Sep-302019-Jun-302019-Mar-312018-Dec-312018-Sep-302018-Jun-302018-Mar-312017-Dec-312017-Sep-302017-Jun-302017-Mar-312016-Dec-312016-Sep-302016-Jun-302016-Mar-312015-Dec-312015-Sep-302015-Jun-302015-Mar-312014-Dec-312014-Sep-302014-Jun-302014-Mar-31
Fiscal PeriodQ4-FY2025Q3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023Q3-FY2023Q2-FY2023Q1-FY2023Q4-FY2022Q3-FY2022Q2-FY2022Q1-FY2022Q4-FY2021Q3-FY2021Q2-FY2021Q1-FY2021Q4-FY2020Q3-FY2020Q2-FY2020Q1-FY2020Q4-FY2019Q3-FY2019Q2-FY2019Q1-FY2019Q4-FY2018Q3-FY2018Q2-FY2018Q1-FY2018Q4-FY2017Q3-FY2017Q2-FY2017Q1-FY2017Q4-FY2016Q3-FY2016Q2-FY2016Q1-FY2016Q4-FY2015Q3-FY2015Q2-FY2015Q1-FY2015Q4-FY2014Q3-FY2014Q2-FY2014Q1-FY2014
Operating Cash Flow(5,299,345$)(7,021,416$)(8,555,222$)(12,469,699$)(12,036,845$)(7,974,917$)(13,224,298$)(9,972,687$)500,440$(8,024,914$)(13,357,836$)(9,443,818$)(11,231,177$)(12,574,218$)(19,958,593$)(12,873,199$)(11,577,699$)(8,434,100$)(9,072,367$)(13,471,741$)(8,317,197$)(6,237,452$)(7,579,054$)(15,359,752$)(11,226,323$)(8,315,046$)(12,810,879$)(12,631,978$)(7,968,175$)(7,688,672$)(7,954,593$)(5,018,517$)(4,705,604$)
Investing Cash Flow16,000,000$25,000,000$(554,126$)7,290,414$(1,563,871$)5,262,615$(18,237,879$)(30,376,620$)0$0$0$30,000,000$27,000,000$19,015,976$(17,938,720$)(58,031,786$)0$0$0$(7,806$)0$5,500,000$17,300,000$6,223,910$(4,285,156$)5,675,527$7,922,026$9,164,454$(28,972,362$)(21,302$)4,801,481$(8,109,975$)(3,627,932$)
Purchases of Property and Equipment0$0$0$16,317$0$0$0$7,806$0$0$4,604$4,925$14,584$47,619$61,757$139,006$13,167$0$0$11,592$0$0$2,576$9,234$0$54,243$30,435$1,441$7,955$
Financing Cash Flow0$120,746$0$1,002,810$7,779$(197,392$)0$18,191$(1,012,312$)(315,759$)5,292$52,559$0$1,196,768$0$23,324$0$63,778$120,368,998$74,063,615$1$26,224,125$12,424,917$3,252,983$8,333,106$14,844,158$(9,138$)407,607$66,289,357$1,112,952$4,093,316$47,980$26,827,643$
End Cash Position70,041,254$59,340,599$41,241,269$50,350,617$54,527,092$68,120,029$71,029,723$102,491,900$142,823,016$143,334,888$151,675,561$165,028,105$144,419,364$128,650,541$121,012,015$158,909,328$229,790,989$241,368,688$249,739,010$138,442,379$77,858,311$86,175,507$60,688,834$38,542,971$44,425,830$51,604,203$39,399,564$44,297,555$47,357,472$18,008,652$24,605,674$20,963,541$20,023,337$33,103,849$14,609,742$12,015,061$12,015,061$14,568,508$17,607,522$14,648,866$14,648,866$30,618,365$33,569,784$15,721,097$8,527,304$10,142,137$11,535,788$2,145,621$
Exchange Rate Effect
Dividends Paid
Unlevered Free Cash Flow(5,299,345$)(7,021,416$)(8,555,222$)(12,469,699$)(12,036,845$)(7,974,917$)(13,224,298$)(9,972,687$)500,440$(8,024,914$)(13,357,836$)(9,443,818$)(11,231,177$)(12,574,218$)(19,958,593$)(12,889,516$)(11,577,699$)(8,434,100$)(9,072,367$)(13,479,547$)(8,317,197$)(6,237,452$)(7,579,054$)(15,359,752$)(11,226,323$)(8,315,046$)(12,815,483$)(12,636,903$)(7,982,759$)(7,736,291$)(8,093,599$)(5,031,684$)(4,705,604$)